We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+24.96%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.96B
AUM Growth
+$343M
Cap. Flow
-$159M
Cap. Flow %
-5.39%
Top 10 Hldgs %
65.85%
Holding
44
New
9
Increased
15
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$43.6M
2
VERA icon
Vera Therapeutics
VERA
+$41.6M
3
PLRX icon
Pliant Therapeutics
PLRX
+$38.8M
4
JANX icon
Janux Therapeutics
JANX
+$36.4M
5
ONC
BeOne Medicines Ltd
ONC
+$36M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$150M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$95.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$90.6M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$79.7M
5
IRON icon
Disc Medicine
IRON
+$56.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
26
Spyre Therapeutics
SYRE
$9.11B
$37.3M 1.26%
+1,267,581
New +$35.3M
PLRX icon
27
Pliant Therapeutics
PLRX
$65M
$34.8M 1.18%
+3,104,486
New +$38.8M
PCVX icon
28
CALL
Vaxcyte
PCVX
$7.9B
$31.6M 1.07%
+276,800
New +$24.9M
KROS icon
29
Keros Therapeutics
KROS
$203M
$30.5M 1.03%
+525,037
New +$25.9M
ERAS icon
30
Erasca
ERAS
$6.38B
$29.1M 0.99%
10,668,141
+3,418,141
+47% +$9.63M
ORKA
31
Oruka Therapeutics
ORKA
$5.92B
$17.6M 0.6%
+719,660
New +$25M
CATX icon
32
Perspective Therapeutics
CATX
$342M
$12.3M 0.42%
919,692
– –
CMPS
33
Compass Pathways
CMPS
$1.59B
$7.31M 0.25%
1,160,000
-1,175,926
-50% -$8.3M
ACRV icon
34
Acrivon Therapeutics
ACRV
$66.8M
– –
-659,724
Closed -$3.83M
ALXO icon
35
ALX Oncology
ALXO
$265M
– –
-1,575,605
Closed -$9.5M
ASND icon
36
Ascendis Pharma A/S
ASND
$16B
– –
-664,307
Closed -$90.6M
BBIO icon
37
BridgeBio Pharma
BBIO
$16.1B
– –
-1,089,492
Closed -$27.6M
LEGN icon
38
Legend Biotech
LEGN
$3.7B
– –
-1,203,308
Closed -$53.3M
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.73B
– –
-947,574
Closed -$150M
TCRX icon
40
TScan Therapeutics
TCRX
$48.1M
– –
-353,886
Closed -$2.07M
VOR icon
41
Vor Biopharma
VOR
$1.21B
– –
-322,865
Closed -$6.46M
VRNA
42
DELISTED
Verona Pharma
VRNA
– –
-721,087
Closed -$10.4M
XENE icon
43
Xenon Pharmaceuticals
XENE
$6.19B
– –
-2,043,280
Closed -$79.7M
CERE
44
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-2,330,508
Closed -$95.3M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Paradigm Biocapital Advisors held 44 positions worth $2.96B, up 13% from $2.61B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Paradigm Biocapital Advisors withdrew a net $159M in Q3 2024, closing 11 positions and reducing 7 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $150M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

Against the trend, Paradigm Biocapital Advisors opened a new position in MoonLake Immunotherapeutics worth $47M.

  • Paradigm Biocapital Advisors's largest Q3 2024 buy was MoonLake Immunotherapeutics: 931,480 shares worth $47M.
  • Paradigm Biocapital Advisors added most to Janux Therapeutics in Q3 2024, an estimated $36.4M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2024 reduction was Disc Medicine, cutting an estimated $56.7M.
  • Paradigm Biocapital Advisors fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $150M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 66% of its $2.96B portfolio in Q3 2024.
  • Paradigm Biocapital Advisors opened 9 new positions and closed 11 in Q3 2024.
  • Paradigm Biocapital Advisors's portfolio value rose 13% quarter-over-quarter to $2.96B.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.